Use of zoledronic acid in thalassemia-induced osteoporosis: Two case reports and review of the literature;Talasemi Osteoporozunda Zoledronik Asit Kullanımı: İki Olgu Sunumu ve Literatürün Gözden Geçirilmesi

Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi

Volumn 58, Issue 2, 2012, Pages 154-158

  Yiǧitoǧlu, Pembe Hare ^a   Güzel, Rengin ^a   Evran, Mehtap ^b   Gürkan, Emel ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b Kahramanmaras Devlet Hastanesi   (Turkey)

Author keywords

Osteoporosis; Thalassemia; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

BLOOD TRANSFUSION; CASE REPORT; DRUG CHOICE; EARLY DIAGNOSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; IRON CHELATION; LIFESPAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; PATHOGENESIS; REVIEW; SECONDARY OSTEOPOROSIS; THALASSEMIA INDUCED OSTEOPOROSIS; THALASSEMIA MAJOR;

EID: 84864007840     PISSN: 13020234     EISSN: None     Source Type: Journal    
DOI: 10.4274/tftr.57704     Document Type: Review

References (27)

1. Tyler PA, Madani G, Chaudhuri R, Wilson LF, Dick EA. The radiological appearances of thalassaemia. Clin Radiol 2006;61:40-52.
2. Evren M. Beta talasemili hastalarda osteoporoz ve osteoporoz tedavisinde zoledronik asit kullani{dotless}mi{dotless} (ti{dotless}pta uzmanli{dotless}k tezi). Adana: Çukurova Üniversitesi; 2005.
3. Ki{dotless}li{dotless}nç M, Koçak F, Yüreǧir G, Aksoy K. İçel ilinde orak hücre anemisi ve β-talasemi taşi{dotless}yi{dotless}ci{dotless}li{dotless}k si{dotless}kli{dotless}ǧi{dotless}. Ç. Ü. Ti{dotless}p Fakültesi Dergisi 1999;24:62-5.
4. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000;111:461-6.
5. Baytan B, Saǧlam H, Erdöl Ş, Beyazi{dotless}t AN, Özgür T, Güneş AM, ve ark. Talasemi majörlü vakalarda endokrin komplikasyonlari{dotless}n deǧerlendirilmesi. Güncel Pediatri 2008;6:58-65.
6. Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporos Int 2010;21:183-7.
7. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with betathalassaemia. Ann Hematol 2007;86:23-30.
8. Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 2010;1202:237-43.
9. Gaudio A, Morabito N, Xourafa A, Macrì I, Meo A, Morgante S, et al. Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J Endocrinol Invest 2008;31:181-4.
10. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11(3 suppl):795-801.
11. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-39.
12. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998;103:911-5.
13. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, et al. Biphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002;13:644-9.
14. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br J Haematol 2003;123:730-7.
15. Pati{dotless}roǧlu T, Altuner Torun Y, Kula M, Karakükçü M. Treatment of thalassemia-induced osteoporosis with intermittent pamidronate infusions: two-year follow-up. Turk J Hematol 2008;25:79-82.
16. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, et al. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a singlecenter, randomized, placebo-controlled trial. Haematologica 2006;91:1193-202.
17. Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemiainduced osteoporosis: long term follow up a randomized, placebocontrolled trial. Haematologica 2008;93:1588-90.
18. Perifanis V, Vyzantiadis T, Vakalopoulou S, Tziomalos K, Garypidou V, Athanassiou-Metaxa M, et al. Treatment of beta-thalassaemiaassociated osteoporosis with zoledronic acid. Br J Haematol 2004;125:91-2.
19. Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M, et al. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 2006;79:138-44.
20. The International Society for Clinical Densitometry. 2007 ISCD Official Positions Brochure. Available from: http://www.iscd.org/Visitors/pdfs/ISCD2007OfficialPositions-Combined-AdultandPediatric.pdf. Accessed: April 17, 2011.
21. Genant HK, Grampp S, Glüer CC, Faulkner KG, Jergas M, Engelke K, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994;9:1503-14.
22. Fan B, Lu Y, Genant H, Fuerst T, Shepherd J. Does standardized BMD stil remove differences between Hologic and GE-Lunar state-of-the-art DXA systems? Osteoporos Int 2010;21:1227-36.
23. Voskaridou E, Christoulas D, Antoniadou L, Terpos E. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. Acta Haematol 2008;119:40-4.
24. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7.
25. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
26. John Camm A. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 2010;32:426-36.
27. Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D, et al. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 2010;3:451-8.